Cambridge spinout Definigen has boosted its intellectual property portfolio by licensing additional research from the university.
Definigen, a stem cell spinout of Cambridge University, licensed additional research from the institution’s tech transfer arm Cambridge Enterprise yesterday in the form of cholangiocyte liver technology.
Cholangiocytes are specialised liver cells that form the bile duct. Diseases of these cells are the underlying cause for 30% of liver transplants.
The technology, which uses induced pluripotent stem cells to generate cholangiocytes, will enable Definigen to create optimised liver cell products and services for applications including disease modelling, drug screening and…
